by TractManager | Sep 22, 2020 | Emerging Technology Report
Viltepso (viltolarsen) is an intravenously administered antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.If you have a Hayes login,...
by TractManager | Sep 21, 2020 | Health Technology Assessment
Focus of the Report: This report evaluates the use of voretigene neparvovec-rzyl (Luxturna) for the treatment of vision loss due to inherited retinal dystrophies (IRDs) from confirmed biallelic RPE65 mutations.Technology Description: Voretigene neparvovec-rzyl is an...
by TractManager | Sep 16, 2020 | Health Technology Assessment
Focus of the Report: This report focuses on amniotic allograft (AA) for treatment or prevention of tendon and ligament injuries.Technology Description: AA is prepared from sheets of amniotic membrane obtained shortly after caesarean delivery. For some products,...
by TractManager | Sep 14, 2020 | Emerging Technology Report
Retevmo (selpercatinib) is a novel oral highly selective RET inhibitor for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, and adult and...
by TractManager | Sep 10, 2020 | Precision Medicine Insights
Focus of Report: This report reviews clinical study abstracts and clinical practice guidelines addressing genetic testing for monogenic systemic autoinflammatory disorders (SAIDs). Autoinflammatory disorders that result from polygenic or multifactorial causes are not...
Recent Comments